Le Lézard
Classified in: Health
Subject: PDT

MaxorPlus to Offer Pharmacy Trend Guarantee


AMARILLO, Texas, Feb. 15, 2018 /PRNewswire/ -- Today, MaxorPlus introduced its Trend Guarantee solution, a proprietary cost containment model aimed at reining in escalating drug costs for Pharmacy Benefit Management (PBM) clients. This solution combines innovative member engagement strategies with industry-leading analytics and clinical programs to deliver guaranteed results on clients' per member per month (PMPM) drug spend.

Maxor Logo

The company's member engagement strategies include its GuidedValuetm member experience ? a mobile device interaction experience aimed at eliminating health literacy barriers by actively navigating patients to make better drug choices.

MaxorPlus' analytics and clinical programs include the Maxor Clinical Analysis Tool (MCAT) - a 65-point clinical inspection on pharmacy claims - and a configurable set of clinical programs that address savings opportunities identified in the MCAT.

Combined, these capabilities enable MaxorPlus to deliver a comprehensive solution that creates a better member experience, lowers costs, improves outcomes, and guarantees financial results.

"MaxorPlus is dedicated to developing new solutions that reduce unnecessary pharmacy costs for our clients. We are excited to launch a solution that combines our competitive pricing, robust analytics, member engagement tools, and clinical strategies to better manage our clients' healthcare dollars," said Mike Ellis, RPh, CEO, Maxor National Pharmacy Services (Maxor).

"The member engagement platform, combined with advanced analytics and clinical expertise, vastly improves members' abilities to navigate their pharmacy benefit, understand opportunities that will lower out-of-pocket expenses, and improve their health," said Michael Einodshofer, RPh, MBA, Chief Innovation Officer, Maxor.

Plan sponsors interested in MaxorPlus' Trend Guarantee solution can visit www.ABetterPBM.com to learn more.  

About Maxor

Maxor is a market-leading Pharmacy Benefit Manager that offers innovative clinical management, analytics, and member engagement strategies to help clients optimize pharmacy spend and health outcomes. Maxor's PBM platform is complemented by Maxor Pharmacy Management & Consulting Services, a provider of outpatient pharmacy management solutions, and Maxor Specialty, a clinically-driven specialty pharmacy focused on rare and orphan diseases. These capabilities allow Maxor to offer customized solutions to diverse market segments including hospitals and health centers, employers, labor groups, and public entities.

SOURCE Maxor


These press releases may also interest you

at 05:25
PureTech Health plc ("PureTech" or the "Company") today announces its results for the year ended December 31, 2023, as well as its cash balance as of the first quarter ended March 31, 2024. The following information represents select highlights from...

at 05:11
Hyundai Bioscience announced on April 25th that its clinical development plan of oral "Niclosamide Metabolic Anticancer Drug" targeting cancer patients with intractable cancer caused by p53 gene mutations. Mutations in the p53 gene occur in almost...

at 04:31
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CHINA, HONG KONG, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR...

at 04:30
The Balance RehabClinic, renowned for its luxury mental health and addiction services, proudly announces its expansion into The Balance Healthcare Group: a collection of premium mental health solutions tailored for affluent individuals. These new...

at 03:47
Zest Dental Solutions, a global leader in innovative dental solutions proudly announces a strategic partnership with The Pathway. Founded by Justin Moody, DDS and based in Arizona, The Pathway is a continuing education program that teaches dentists...

at 03:34
Medivir AB (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its selective cathepsin K inhibitor, MIV-711, has been granted Rare Pediatric Disease...



News published on and distributed by: